Pre-eclampsia, a life-threatening condition characterised by high blood pressure and protein in the urine during pregnancy, causes more than 70,000 maternal deaths annually worldwide, according to BBC News. Researchers are now exploring novel therapeutic approaches to prevent progression and reduce the burden of this condition, which remains one of the leading causes of maternal mortality globally.
Pre-eclampsia: Global maternal mortality burden
Estimated annual deaths and affected pregnancies, global estimates
Source: World Health Organization, BBC News | Georgian Medical Journal News
Why pre-eclampsia remains a critical maternal health challenge
Pre-eclampsia and eclampsia (its severe form with seizures) account for approximately 14% of maternal deaths globally, with particularly high mortality in low- and middle-income countries where monitoring and emergency obstetric care are limited. The condition typically develops after 20 weeks of gestation and can progress rapidly, endangering both mother and fetus.
Current management relies primarily on blood pressure control and delivery of the baby as the only definitive cure, yet prevention strategies remain underdeveloped. This has prompted international research efforts to identify biological mechanisms and explore targeted interventions that could halt disease progression before severe complications emerge.
Emerging therapeutic targets and research directions
Recent investigations have focused on understanding the underlying pathophysiology of pre-eclampsia, including placental dysfunction and endothelial injury. According to research published in The Lancet and related maternal health literature, potential new treatments under investigation include agents targeting placental growth factor (PlGF) dysregulation and inflammatory pathways that characterise the condition.
These approaches represent a shift from symptomatic management toward addressing the root biological causes. Early-phase research suggests that interventions targeting angiogenic imbalance—the disruption of blood vessel formation and function—may offer new opportunities for prevention and treatment in high-risk populations.
Pre-eclampsia causes more than 70,000 maternal deaths annually worldwide, yet remains a condition for which prevention and early-stage treatment options are critically limited.
— World Health Organization / BBC News
Implications for maternal healthcare and global health policy
The development of novel pre-eclampsia treatments could significantly reduce maternal mortality in settings where access to high-dependency obstetric care is constrained. Earlier identification and targeted intervention, rather than emergency delivery, would provide clinicians with additional tools to manage this condition safely.
Efforts to translate new therapies into clinical practice will require robust clinical trials, particularly in low-resource settings where pre-eclampsia burden is highest. International collaboration on women and children’s health initiatives is essential to ensure equitable access to any advances and to strengthen health policy frameworks that support early detection and evidence-based management. Continued investment in maternal health research remains critical to achieving global maternal mortality reduction targets.
Key takeaways
- Pre-eclampsia causes more than 70,000 maternal deaths annually, making it a leading cause of maternal mortality globally
- Current treatment relies on blood pressure control and delivery; new therapies targeting underlying biological mechanisms are under investigation
- Emerging approaches focus on placental growth factor dysregulation and endothelial dysfunction as potential intervention points
- Clinical translation of new treatments will require robust trials in diverse populations, particularly in low- and middle-income countries where burden is highest
Frequently asked questions
What exactly is pre-eclampsia?
Pre-eclampsia is a pregnancy-related disorder characterised by high blood pressure (≥140/90 mmHg) and protein in the urine, occurring after 20 weeks of gestation. If left untreated, it can progress to eclampsia—a severe form involving seizures and potentially fatal complications for mother and baby. It affects 3–5% of pregnancies globally.
Why is pre-eclampsia so dangerous?
Pre-eclampsia can cause placental abruption, stroke, kidney failure, liver damage, and fetal complications including growth restriction and stillbirth. The condition can develop and worsen rapidly, and currently, the only definitive treatment is delivery of the baby, which may be necessary prematurely and carry additional risks.
How might new treatments change care?
Novel therapies targeting the biological causes of pre-eclampsia—such as placental dysfunction and inflammatory pathways—could allow clinicians to halt disease progression earlier, avoid premature delivery in some cases, and reduce emergency complications. This would particularly benefit pregnant people in settings with limited access to intensive obstetric care.
As research advances and new therapeutic agents move toward clinical trials, the potential to transform pre-eclampsia management from emergency intervention to targeted prevention offers genuine hope for reducing maternal mortality on a global scale. Collaborative international efforts to develop, test, and implement these innovations in diverse healthcare settings will be essential to realizing their full benefit.
Source: BBC News: Potential new treatment for pre-eclampsia
